| 產(chǎn)品名稱(chēng) |
Mumps rubulavirus |
| 商品貨號(hào) |
B195140 |
| Classification |
Paramyxoviridae, Rubulavirus |
| Deposited As |
Mumps |
| Agent |
Mumps rubulavirus |
| Strain |
Jones |
| Common Name |
Mumps virus |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation |
Throat washing one day after onset of parotitis |
| Product Format |
frozen |
| Storage Conditions |
-70°C or colder |
| Comments |
VR-1438 is a mycoplasma-free strain of Mumps derived at the ATCC® from VR-365 by three passages in the
presence of MP Biomedicals Mycoplasma Removal Agent, (4-oxoquinoline-3-carboxylic
acid derivative). The most accurate method of titration to confirm infectivity endpoint is the hemadsorption technique. The Jones strain was passaged extensively in CE and CE TC to attenuate it for humans. |
| Effect on Host |
Yes, in vitro effects: Cytopathic effects in tissue culture CPE, cell degeneration, and sloughing |
| Recommended Host |
chicken embryo fibroblasts Recommended Host: SL-29 cells (ATCC? CRL-1590?) chicken embryo fibroblasts; human kidney cells; marmoset kidney cells; rhesus monkey kidney cells; HEp-2 cells (ATCC CCL-23) |
| Growth Conditions |
Temperature: 37.0°C Duration: 5-7 days |
| Name of Depositor |
F Deinhardt, G Shramek |
| Special Collection |
NCRR Contract |
| Source |
Throat washing one day after onset of parotitis |
| References |
Shramek G, Deinhardt F. Development of an attenuated mumps virus vaccine. II. Immune response of animals to vaccination with inactivated and live attenuated mumps viruses. J. Immunol. 102: 1093-1098, 1969. PubMed: 5768187
|
